2023
Association of Recent and Past Suicide Attempts With Health-Related Quality of Life.
Bommersbach T, Rosenheck R, Rhee T. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36856537, DOI: 10.4088/jcp.22m14441.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol-Related DisordersCost-Benefit AnalysisHumansMental HealthQuality of LifeSuicide, AttemptedConceptsMental component scorePhysical component scoreSuicide prevention initiativesSuicide attemptsOverall health-related qualityMajor public health priorityPrevention initiativesHealth-related qualitySubstance use comorbiditiesMeasures of HRQOLRelated Conditions Wave IIILower MCS scoresMultivariable regression analysisPublic health prioritySubstance use disordersComponent scoresNational Epidemiologic SurveyQuality of lifeRecent suicide attemptAssociation of suicidePast suicide attemptsPrior attemptsMCS scoresUnadjusted analysesHealth priority
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsComparative Effectiveness ResearchCost-Benefit AnalysisDrug CostsHealth PolicyHumansSchizophreniaUnited StatesConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysisEvaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck R. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. The British Journal Of Psychiatry 2007, 191: 238-245. PMID: 17766765, DOI: 10.1192/bjp.bp.106.035063.Peer-Reviewed Original ResearchDr. Rosenheck and Colleagues Reply
ROSENHECK R, STROUP T, SWARTZ M, McEVOY J, DAVIS S, KEEFE R, HSIAO J, LIEBERMAN J. Dr. Rosenheck and Colleagues Reply. American Journal Of Psychiatry 2007, 164: 678-680. PMID: 17403984, DOI: 10.1176/ajp.2007.164.4.678a.Peer-Reviewed Original ResearchPractical applications of recent antipsychotic effectiveness data.
Lieberman J, Harvey P, Newcomer J, Rosenheck R. Practical applications of recent antipsychotic effectiveness data. The Journal Of Clinical Psychiatry 2007, 68: 151-62. PMID: 17284143, DOI: 10.4088/jcp.v68n0120.Peer-Reviewed Original Research
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment Outcome
2003
Cost-effectiveness of Supported Housing for Homeless Persons With Mental Illness
Rosenheck R, Kasprow W, Frisman L, Liu-Mares W. Cost-effectiveness of Supported Housing for Homeless Persons With Mental Illness. JAMA Psychiatry 2003, 60: 940-951. PMID: 12963676, DOI: 10.1001/archpsyc.60.9.940.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase ManagementCommunity-Institutional RelationsCost of IllnessCost-Benefit AnalysisFemaleFinancing, GovernmentGovernment AgenciesHealth Care CostsHealth StatusHumansIll-Housed PersonsMaleMental DisordersProgram EvaluationProspective StudiesPublic HousingSocial AdjustmentSubstance-Related DisordersUnited StatesUnited States Department of Veterans AffairsVeteransConceptsStandard care groupIntensive case managementStandard careCase managementCare groupMore daysMental illnessVeterans AffairsIncremental cost-effectiveness ratioSuperior housing outcomesSubstance abuse statusHUD-VASHMental health statusSubstance abuse disordersCost-effectiveness ratioCommunity adjustmentMental illness resultsSupported housing programsSecondary outcomesPrimary outcomeAbuse disordersIllness resultsControl groupHealth statusSocietal perspective
2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology
Schneider L, Tariot P, Lyketsos C, Dagerman K, Davis K, Davis S, Hsiao J, Jeste D, Katz I, Olin J, Pollock B, Rabins P, Rosenheck R, Small G, Lebowitz B, Lieberman J. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal Of Geriatric Psychiatry 2001, 9: 346-360. PMID: 11739062, DOI: 10.1097/00019442-200111000-00004.Peer-Reviewed Original ResearchBuprenorphine for opiate addiction: potential economic impact
Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug And Alcohol Dependence 2001, 63: 253-262. PMID: 11418229, DOI: 10.1016/s0376-8716(00)00214-3.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCost-Benefit AnalysisCounselingDrug Evaluation, PreclinicalHealth Care CostsHumansMethadoneOpioid-Related DisordersConceptsBuprenorphine/naloxoneBuprenorphine/naloxone therapyBuprenorphine/naloxone combinationOffice-based treatmentHigh-cost patientsNet cost savingsNaloxone therapyToxicology screenMethadone clinicsNaloxone combinationNursing costsTreatment opportunitiesMultiple detoxificationsOpiate addictionNaloxoneOffice practicePatientsComparable groupsAdverse effectsMethadoneTreatmentAddictsNet savingsAddiction
2000
The Delivery of Mental Health Services in the 21st Century: Bringing the Community Back In
Rosenheck R. The Delivery of Mental Health Services in the 21st Century: Bringing the Community Back In. Community Mental Health Journal 2000, 36: 107-124. PMID: 10708049, DOI: 10.1023/a:1001860812441.Peer-Reviewed Original ResearchConceptsCommunity mental health movementMental illnessMental health movementCommunity mental health centerState mental health agenciesPersistent mental illnessSevere mental illnessMental health centersMental health servicesMental health agenciesSafety net servicesIntended target populationHealth centersHealth movementState HospitalHealth servicesIll individualsHealth agenciesTarget populationIllness
1999
Effect of declining mental health service use on employees of a large corporation
Rosenheck R, Druss B, Stolar M, Leslie D, Sledge W. Effect of declining mental health service use on employees of a large corporation. Health Affairs 1999, 18: 193-203. PMID: 10495607, DOI: 10.1377/hlthaff.18.5.193.Peer-Reviewed Original Research
1998
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Services Research 1998, 33: 1237-61. PMID: 9865219, PMCID: PMC1070315.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioRefractory schizophreniaVeterans Affairs Cooperative Study GroupHigh hospital usersIncremental cost-effectiveness ratioDouble-blind trialCooperative Study GroupDisease-specific measuresVA Medical CenterStandard assessment instrumentsMeasures of symptomsMultiple outcome domainsQuality Adjusted Life YearsComposite health indexAdjusted Life YearsHealth indexStudy entryPercent confidence intervalsAverage annual costStandard treatmentCost dataRole functioningStudy groupMedical CenterSide effects
1997
Inpatient Treatment of War-Related Posttraumatic Stress Disorder: A 20-Year Perspective
Rosenheck R, Fontana A, Errera P. Inpatient Treatment of War-Related Posttraumatic Stress Disorder: A 20-Year Perspective. Journal Of Traumatic Stress 1997, 10: 407-413. PMID: 9246648, DOI: 10.1023/a:1024837220247.Peer-Reviewed Original ResearchInpatient treatment of war‐related posttraumatic stress disorder: A 20‐year perspective
Rosenheck R, Fontana A, Errera P. Inpatient treatment of war‐related posttraumatic stress disorder: A 20‐year perspective. Journal Of Traumatic Stress 1997, 10: 407-413. DOI: 10.1002/jts.2490100306.Peer-Reviewed Original Research
1995
Effectiveness and cost of specific treatment elements in a program for homeless mentally ill veterans
Rosenheck R, Frisman L, Gallup P. Effectiveness and cost of specific treatment elements in a program for homeless mentally ill veterans. Psychiatric Services 1995, 46: 1131-1139. PMID: 8564501, DOI: 10.1176/ps.46.11.1131.Peer-Reviewed Original ResearchMeSH KeywordsAdultChronic DiseaseCommunity Mental Health ServicesContract ServicesCost-Benefit AnalysisFemaleHospitals, VeteransHumansIll-Housed PersonsLength of StayLongitudinal StudiesMaleMental DisordersMiddle AgedOutcome and Process Assessment, Health CareSocial AdjustmentSocial EnvironmentSubstance-Related DisordersUnited StatesVeteransConceptsSpecific treatment elementsTreatment elementsIll veteransOutcome measuresResidential treatmentNumber of daysLongitudinal outcome studyNumber of referralsSubstance use disordersMeasures of outcomeVeterans Affairs programsPublic support paymentsProgram cliniciansOutcome studiesClinical contactUse disordersIll personsOutcome domainsEight-month periodHomeless veteransMultimodal approachProgram entryVeteran ProgramTreatmentVeteransIssues in estimating the cost of innovative mental health programs
Rosenheck R, Neale M, Frisman L. Issues in estimating the cost of innovative mental health programs. Psychiatric Quarterly 1995, 66: 9-31. PMID: 7701023, DOI: 10.1007/bf02238713.Peer-Reviewed Original ResearchMeSH KeywordsCommunity Mental Health ServicesCost-Benefit AnalysisHumansUnited StatesVeteransWorkloadConceptsMental health programsInnovative mental health programsHealth programsIntensive psychiatric community careVeterans Affairs Medical CenterPsychiatric community careHealth care servicesDirect programme costsMedical CenterProgram costsCare servicesCommunity careMulti-site studyCase managementIndirect costsStaffing levelsCommunity programsCaseload sizeMultisite Experimental Cost Study of Intensive Psychiatric Community Care
Rosenheck R, Neale M, Leaf P, Milstein R, Frisman L. Multisite Experimental Cost Study of Intensive Psychiatric Community Care. Schizophrenia Bulletin 1995, 21: 129-140. PMID: 7770734, DOI: 10.1093/schbul/21.1.129.Peer-Reviewed Original ResearchConceptsControl patientsHealth care service usageIntensive psychiatric community careVeterans Affairs Medical CenterHigh hospital usersPsychiatric community careStandard VA careInpatient service useCommunity care programProgram entryInpatient usageVA careAge 45Medical CenterSurgical hospitalsService usePatientsCare programCommunity careVA costsSociodemographic characteristicsService usageCareComputerized dataCost studiesClozapine's cost effectiveness.
Rosenheck R, Charney D, Frisman L, Cramer J. Clozapine's cost effectiveness. American Journal Of Psychiatry 1995, 152: 152-3. PMID: 7802113.Peer-Reviewed Original Research
1993
Health Care Utilization and Costs After Entry Into an Outreach Program for Homeless Mentally Ill Veterans
Rosenheck R, Frisman L, Gallup P. Health Care Utilization and Costs After Entry Into an Outreach Program for Homeless Mentally Ill Veterans. Psychiatric Services 1993, 44: 1166-1171. PMID: 8132189, DOI: 10.1176/ps.44.12.1166.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareChronic DiseaseCost-Benefit AnalysisDiagnosis, Dual (Psychiatry)FemaleHospitals, VeteransHumansIll-Housed PersonsLength of StayLongitudinal StudiesMaleMental DisordersMiddle AgedOutpatient Clinics, HospitalPatient AdmissionPatient Care PlanningSubstance-Related DisordersUnited StatesUnited States Department of Veterans AffairsUtilization ReviewVeteransConceptsHealth care servicesCare servicesIll veteransVA health service utilizationClinical needHealth care utilizationHealth service utilizationInitial contactHealth care costsSubstance abuse problemsResidential treatment programCare utilizationService utilizationUse of servicesOutpatient servicesOutreach programsClinical reportsInpatient servicesCare costsHealth servicesMultivariate analysisIll personsTreatment programDischarge summariesIntake instruments